Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06057675 · ClinicalTrials.gov registry record · Phase 2
Tranexamic Acid in Nasal Mohs Reconstruction
A Phase 2 study of Skin Cancer Face and Postoperative Bleeding, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06057675 is a Phase 2 study of Skin Cancer Face and Postoperative Bleeding that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06057675, a Phase 2 study of Skin Cancer Face and Postoperative Bleeding, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered TXA among patients undergoing nasal Mohs reconstruction with local flaps at VUMC.
Conditions Studied
Interventions
- DRUG Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine)
- DRUG Control (1% lidocaine with 1:100,000 epinephrine)
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-03-19 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06057675
The ClinicalTrials.gov registry entry for NCT06057675 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Skin Cancer Face appearing as the primary indexed condition, and to 2 interventions - of which Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine) is the first listed.
NCT06057675 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT06057675 about?
NCT06057675 is a clinical study titled "Tranexamic Acid in Nasal Mohs Reconstruction". This study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered TXA among patients undergoing nasal Mohs reconstruction with local flaps at VUMC.
What is the current status of trial NCT06057675?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2024-03-19. Estimated completion is 2026-06.
What conditions does trial NCT06057675 study?
This clinical trial studies the following conditions: Skin Cancer Face, Postoperative Bleeding.
What interventions are being tested in trial NCT06057675?
The interventions under investigation include: Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine) (DRUG), Control (1% lidocaine with 1:100,000 epinephrine) (DRUG).
Who is sponsoring clinical trial NCT06057675?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06057675 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Cancer Face
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.